State Street Corp Eq Rx, Inc. Transaction History

State Street Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.66 - $2.31 $1.34 Million - $1.86 Million	-807,007 Reduced 7.36%	10,160,585 $22.6 Million
Q2 2023 Aug 14, 2023	SELL	$1.61 - $1.96 $5.14 Million - $6.26 Million	-3,192,879 Reduced 22.55%	10,967,592 $20.4 Million
Q1 2023 May 15, 2023	SELL	$1.8 - $2.83 $2.8 Million - $4.4 Million	-1,553,859 Reduced 9.89%	14,160,471 $27.5 Million
Q4 2022 Feb 14, 2023	BUY	$2.05 - $5.5 $11.1 Million - $29.8 Million	5,423,471 Added 52.7%	15,714,330 $38.7 Million
Q3 2022 Nov 15, 2022	BUY	$0.94 - $5.99 $3.58 Million - $22.8 Million	3,808,893 Added 58.76%	10,290,859 $50.9 Million
Q2 2022 Aug 15, 2022	BUY	$3.2 - $5.69 $18.3 Million - $32.6 Million	5,732,202 Added 764.53%	6,481,966 $30.4 Million
Q1 2022 May 16, 2022	BUY	$2.8 - $7.39 $2.1 Million - $5.54 Million	749,764 New	749,764 $3.1 Million

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.